Marjean T Kulp1, Jonathan M Holmes2, Trevano W Dean3, Donny W Suh4, Raymond T Kraker3, David K Wallace5, David B Petersen6, Susan A Cotter7, Ruth E Manny8, Rosanne Superstein9, Tawna L Roberts10, John M Avallone11, Deborah R Fishman12, S Ayse Erzurum13, David A Leske2, Alex Christoff14. 1. College of Optometry, The Ohio State University, Columbus, Ohio. Electronic address: pedig@jaeb.org. 2. Mayo Clinic, Rochester, Minnesota. 3. Jaeb Center for Health Research, Tampa, Florida. 4. University of Nebraska Medical Center, Omaha, Nebraska. 5. Indiana University, Indianapolis, Indiana. 6. Rocky Mountain Eye Care Associates, Salt Lake City, Utah. 7. Southern California College of Optometry at Marshall B. Ketchum University, Fullerton, California. 8. University of Houston College of Optometry, Houston, Texas. 9. Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada. 10. Byers Eye Institute, Stanford University, Palo Alto, CA. 11. Ophthalmology Associates of Greater Annapolis, Arnold, Maryland. 12. Pediatric Eye Associates, Wilmette, Illinois. 13. Eye Care Associates, Inc., Poland, Ohio. 14. Wilmer Eye Institute, Baltimore, Maryland.
Abstract
PURPOSE: Two strategies were compared for managing moderate hyperopia without manifest strabismus among 1- and 2-year-old children: (1) immediate prescription of glasses versus (2) observation without glasses unless reduced distance visual acuity (VA), reduced stereoacuity, or manifest strabismus. DESIGN: Prospective randomized clinical trial. PARTICIPANTS: A total of 130 children aged 1 to 2 years with hyperopia between +3.00 diopters (D) and +6.00 D spherical equivalent (SE) in at least 1 eye, anisometropia ≤1.50 D SE, and astigmatism ≤1.50 D based on cycloplegic refraction and no manifest strabismus. METHODS: Participants were randomly assigned to glasses (1.00 D less than full cycloplegic hyperopia) versus observation and followed every 6 months for 3 years. Glasses were prescribed to those assigned to observation if they met prespecified deterioration criteria of distance VA or near stereoacuity below age norms, or development of manifest strabismus. MAIN OUTCOME MEASURES: At the 3-year primary outcome examination, participants were classified as failing the randomized management regimen if distance VA or stereoacuity was below age norms or manifest strabismus was observed (each with and without correction in trial frames, confirmed by masked retest, irrespective of whether deterioration had occurred previously), or if strabismus surgery had been performed. RESULTS: Of the 106 participants (82%) completing the 3-year primary outcome examination, failure occurred in 11 (21%) of 53 in the glasses group and 18 (34%) of 53 in the observation group (difference = -13%; 95% confidence interval [CI], -31 to 4; P = 0.14). Sixty-two percent (95% CI, 49-74) in the observation group and 34% (95% CI, 23-48) in the glasses group met deterioration criteria (requiring glasses if not wearing). CONCLUSIONS: For 1- and 2-year-olds with uncorrected moderate hyperopia (+3.00 D to +6.00 D SE), our estimates of failure, after 3 years of 6-month follow-ups, are inconclusive and consistent with a small to moderate benefit or no benefit of immediate prescription of glasses compared with careful observation (with glasses only if deteriorated).
RCT Entities:
PURPOSE: Two strategies were compared for managing moderate hyperopia without manifest strabismus among 1- and 2-year-old children: (1) immediate prescription of glasses versus (2) observation without glasses unless reduced distance visual acuity (VA), reduced stereoacuity, or manifest strabismus. DESIGN: Prospective randomized clinical trial. PARTICIPANTS: A total of 130 children aged 1 to 2 years with hyperopia between +3.00 diopters (D) and +6.00 D spherical equivalent (SE) in at least 1 eye, anisometropia ≤1.50 D SE, and astigmatism ≤1.50 D based on cycloplegic refraction and no manifest strabismus. METHODS:Participants were randomly assigned to glasses (1.00 D less than full cycloplegic hyperopia) versus observation and followed every 6 months for 3 years. Glasses were prescribed to those assigned to observation if they met prespecified deterioration criteria of distance VA or near stereoacuity below age norms, or development of manifest strabismus. MAIN OUTCOME MEASURES: At the 3-year primary outcome examination, participants were classified as failing the randomized management regimen if distance VA or stereoacuity was below age norms or manifest strabismus was observed (each with and without correction in trial frames, confirmed by masked retest, irrespective of whether deterioration had occurred previously), or if strabismus surgery had been performed. RESULTS: Of the 106 participants (82%) completing the 3-year primary outcome examination, failure occurred in 11 (21%) of 53 in the glasses group and 18 (34%) of 53 in the observation group (difference = -13%; 95% confidence interval [CI], -31 to 4; P = 0.14). Sixty-two percent (95% CI, 49-74) in the observation group and 34% (95% CI, 23-48) in the glasses group met deterioration criteria (requiring glasses if not wearing). CONCLUSIONS: For 1- and 2-year-olds with uncorrected moderate hyperopia (+3.00 D to +6.00 D SE), our estimates of failure, after 3 years of 6-month follow-ups, are inconclusive and consistent with a small to moderate benefit or no benefit of immediate prescription of glasses compared with careful observation (with glasses only if deteriorated).
Authors: Susan A Cotter; Nicole C Foster; Jonathan M Holmes; B Michele Melia; David K Wallace; Michael X Repka; Susanna M Tamkins; Raymond T Kraker; Roy W Beck; Darren L Hoover; Eric R Crouch; Aaron M Miller; Christie L Morse; Donny W Suh Journal: Ophthalmology Date: 2011-09-29 Impact factor: 12.079
Authors: J Atkinson; S Anker; W Bobier; O Braddick; K Durden; M Nardini; P Watson Journal: Invest Ophthalmol Vis Sci Date: 2000-11 Impact factor: 4.799
Authors: Jenny M Ip; Dana Robaei; Annette Kifley; Jie Jin Wang; Kathryn A Rose; Paul Mitchell Journal: Ophthalmology Date: 2007-07-30 Impact factor: 12.079
Authors: Eileen Birch; Cathy Williams; James Drover; Valeria Fu; Christina Cheng; Kate Northstone; Mary Courage; Russell Adams Journal: J AAPOS Date: 2007-08-27 Impact factor: 1.220
Authors: Xuejuan Jiang; Kristina Tarczy-Hornoch; Douglas Stram; Joanne Katz; David S Friedman; James M Tielsch; Saiko Matsumura; Seang-Mei Saw; Paul Mitchell; Kathryn A Rose; Susan A Cotter; Rohit Varma Journal: Ophthalmology Date: 2019-02-26 Impact factor: 12.079